ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions
Open Access
- 1 August 2002
- journal article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 36 (2) , 439-450
- https://doi.org/10.1053/jhep.2002.34435
Abstract
Quantitative immunohistochemistry of ERBB-2 and MET receptor proteins and of cyclooxygenase 2 (COX-2) was undertaken to determine if there is a positive correlation between overexpression of either ERBB-2 or MET and up-regulation of COX-2 in human cholangiocarcinogenesis. ERBB-2, MET, and COX-2 immunoreactivities were measured in cancerous parenchyma of 71 archival cases of human cholangiocarcinoma (ChC) compared with hyperplastic small biliary ducts in surrounding nonneoplastic liver and with bile ducts of normal adult human liver. ERBB-2, MET, and COX-2 immunoreactivities were also assessed in both large and small hyperplastic biliary ducts (HBDs) in 27 archival cases of hepatolithiasis and 20 archival cases of primary sclerosing cholangitis (PSC), both of which are risk conditions for human cholangiocarcinogenesis. There was a strong positive correlation between increased ERBB-2, but not MET, and COX-2 immunoreactivity measured in the tumors and risk conditions. Enhanced immunoreactivity for ERBB-2 and COX-2 also correlated directly with tumor differentiation and was highest in well-differentiated tumors. Interestingly, some but not all cases of hepatolithiasis and most cases of PSC showed increased ERBB-2 and COX-2 immunostaining in the large but not small HBDs, whereas strong MET immunostaining was detected in both the large and small ducts. In conclusion, overexpression of ERBB-2 and COX-2 may herald an early carcinogenic event in the human hepatic biliary tract and one that is consistent with a frequent anatomic site of origin of the tumors. The results also suggest ERBB-2 and COX-2 as potentially important targets relevant to chemoprevention or adjunct therapy of ChC.Keywords
Funding Information
- National Institutes of Health (R01 CA 83650)
- Merck & Co., Inc. to A.E.S. (Vioxx MSGP 284 “C”)
- National Institutes of Health to A.J.D. (DK 49615)
This publication has 27 references indexed in Scilit:
- Differential expression of cyclooxygenase-2 (COX-2) in human bile duct epithelial cells and bile duct neoplasmHepatology, 2001
- The genetics of pancreatic adenocarcinoma: a roadmap for a mouse modelSeminars in Cancer Biology, 2001
- Aberrant cyclooxygenase isozyme expression in human intrahepatic cholangiocarcinomaGut, 2001
- Human ovarian surface epithelial (OSE) cells express LH/hCG receptors, and HCG inhibits apoptosis of OSE cells via up‐regulation of insulin‐like growth factor‐1International Journal of Cancer, 2000
- Comparative clinicopathological study of resected intrahepatic cholangiocarcinoma in northeast Thailand and JapanJournal of Hepato-Biliary-Pancreatic Surgery, 2000
- Overexpression of C–Neu and C–Met During Rat Liver Cholangiocarcinogenesis: A Link Between Biliary Intestinal Metaplasia and Mucin–Producing CholangiocarcinomaHepatology, 1999
- Regulation of Cyclooxygenase-2 pathway by HER2 receptorOncogene, 1999
- c-erbB-2 oncogene expression in hepatocellular carcinoma and cholangiocarcinomaJournal of Hepatology, 1992
- Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections.Journal of Histochemistry & Cytochemistry, 1991
- Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.Journal of Histochemistry & Cytochemistry, 1981